Specific behavioral and cellular adaptations induced by chronic morphine are reduced by dietary omega-3 polyunsaturated fatty acids

Autor: Camille Johnston, Ani Minasyan, Nicole Romaneschi, Joshua K. Hakimian, Fernando Gomez-Pinilla, Waleed Atallah, Wendy Walwyn, Alexander Vorperian, Austin Beltrand, Mariana Loureiro, Lily Zhe-Ying
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
Physiology
lcsh:Medicine
Anxiety
Euphoriant
Running
Mice
0302 clinical medicine
Medicine and Health Sciences
Receptor
lcsh:Science
chemistry.chemical_classification
Analgesics
Multidisciplinary
Morphine
Neuronal Morphology
Pharmaceutics
Drugs
Brain
Lipids
3. Good health
Frontal Lobe
Receptors
Glutamate

Dopamine receptor
Female
Opiate
μ-opioid receptor
Anatomy
Locomotion
Polyunsaturated fatty acid
medicine.drug
Research Article
medicine.medical_specialty
Motor Activity
Real-Time Polymerase Chain Reaction
Drug Administration Schedule
03 medical and health sciences
Drug Therapy
Internal medicine
Fatty Acids
Omega-3

medicine
Pain Management
Animals
Maze Learning
Nutrition
Pharmacology
business.industry
Biological Locomotion
lcsh:R
Biology and Life Sciences
Corpus Striatum
Diet
Opioids
Neostriatum
Mice
Inbred C57BL

030104 developmental biology
Endocrinology
chemistry
Opioid
Cellular Neuroscience
lcsh:Q
Analgesia
business
030217 neurology & neurosurgery
Neuroscience
Zdroj: PLoS ONE
PLoS ONE, Vol 12, Iss 4, p e0175090 (2017)
ISSN: 1932-6203
Popis: Opiates, one of the oldest known drugs, are the benchmark for treating pain. Regular opioid exposure also induces euphoria making these compounds addictive and often misused, as shown by the current epidemic of opioid abuse and overdose mortalities. In addition to the effect of opioids on their cognate receptors and signaling cascades, these compounds also induce multiple adaptations at cellular and behavioral levels. As omega-3 polyunsaturated fatty acids (n-3 PUFAs) play a ubiquitous role in behavioral and cellular processes, we proposed that supplemental n-3 PUFAs, enriched in docosahexanoic acid (DHA), could offset these adaptations following chronic opioid exposure. We used an 8 week regimen of n-3 PUFA supplementation followed by 8 days of morphine in the presence of this diet. We first assessed the effect of morphine in different behavioral measures and found that morphine increased anxiety and reduced wheel-running behavior. These effects were reduced by dietary n-3 PUFAs without affecting morphine-induced analgesia or hyperlocomotion, known effects of this opiate acting at mu opioid receptors. At the cellular level we found that morphine reduced striatal DHA content and that this was reversed by supplemental n-3 PUFAs. Chronic morphine also increased glutamatergic plasticity and the proportion of Grin2B-NMDARs in striatal projection neurons. This effect was similarly reversed by supplemental n-3 PUFAs. Gene analysis showed that supplemental PUFAs offset the effect of morphine on genes found in neurons of the dopamine receptor 2 (D2)-enriched indirect pathway but not of genes found in dopamine receptor 1(D1)-enriched direct-pathway neurons. Analysis of the D2 striatal connectome by a retrogradely transported pseudorabies virus showed that n-3 PUFA supplementation reversed the effect of chronic morphine on the innervation of D2 neurons by the dorsomedial prefontal and piriform cortices. Together these changes outline specific behavioral and cellular effects of morphine that can be reduced or reversed by dietary n-3 PUFAs.
Databáze: OpenAIRE